osmetech - 500 Beiträge pro Seite

[tomhead]

@all
hier ein paar Infos. In England wird sie unter dem Kürzel OMH gehandel und zwar nicht schlecht.

Hier die Homepage
www.osmetech.plc.uk
mal sehen was da nächste Woche so an Zahlen kommt.
Bis dahin
tomhead

[tomhead]

ok, die Zahlen waren nicht so gut. Mal sehen was die Zukunft bring.

Osmetech plc


Interim Results for the six months ending 31st October 2004

Highlights


· Acquisition of Molecular Sensing plc (‘MS’ successfully completed

· License signed for LGC HyBeacons DNA probe technology

· Sales of £2,442,000 (2003 - £3,457,000) in line with expectations

· Strong growth to commence in the second half with IDEXX veterinary sales and new product launches



James White, Chief Executive, Osmetech plc said:



‘Osmetech’s strategic objective to develop an international diagnostics business in the high growth point of care and near patient testing market has continued to show good progress.



‘The highly successful acquisition of the OPTI product line of blood gas analyzers in 2003 provided us a high quality infrastructure to support the organic growth of the Group’s business as well as providing us with a solid revenue base.



‘The current financial year will see the start of a significant growth period for OPTI, through both new product introductions and the commencement of the IDEXX trading relationship. IDEXX is a worldwide leader in the development and commercialisation of animal health diagnostic products, delivering sales of $475 million in 2003 and with a market capitalisation of approximately $1.9 billion.



‘We also expect to be able to grow the business through suitable acquisitions and are delighted to report the important recent acquisition of MS. This further strengthens the Group’s product pipeline by providing an instrument in late stage development for DNA and RNA analysis, ‘Opti GENE’ (previously known as ‘Genedrive’. We initially intend to sell the Opti GENE into the rapidly growing genetic testing and infectious disease testing market segments.



‘MS has been integrated into the Group and we have already secured a key license agreement with LGC giving us access to their HyBeacons DNA probe technology. Using this technology we will finalise existing tests and to develop new tests specifically designed for use with the Opti GENE instrument which will be exhibited for the first time later this year.’



For further information:



Osmetech plc

James White/David Sandilands 020 7378 7033 (Thursday 27th January)

020 7849 6027 thereafter

madano partnership

Matthew Moth/Adam Wurf 020 7378 7033




tomhead